n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
ARIAD Presents Updated Clinical Data On AP26113 In Patients With ALK+ Non-Small Cell Lung Cancer

ARIAD Presents Updated Clinical Data On AP26113 In Patients With ALK+ Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from...

ARIA: Insiders vs. Shorts

ARIA: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 09/15/2014 settlement date, and ARIAD Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 10.65 "days to cover" versus the median component at 6.91.

Ariad Director Resignation May Mean CEO Berger One Step Closer to Exit

Ariad Director Resignation May Mean CEO Berger One Step Closer to Exit

Activist investor Alex Denner is gaining an ally on Ariad's Board.

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

Biotech columnist Adam Feuerstein answers readers' questions about health care.

'Mad Money' Lightning Round: Yahoo! Is One of the Best Buys Around

'Mad Money' Lightning Round: Yahoo! Is One of the Best Buys Around

Cramer likes Araid Pharmaceuticals and Occidental Petroleum and is sticking with his Taser recommendation.

Jim Cramer's 'Mad Money' Recap: These Are 3 Stocks Cramer Trusts

Jim Cramer's 'Mad Money' Recap: These Are 3 Stocks Cramer Trusts

Cramer wants Apple, Microsoft and Dow Chemical on his team.

ARIA Makes Bullish Cross Above Critical Moving Average

ARIA Makes Bullish Cross Above Critical Moving Average

In trading on Tuesday, shares of ARIAD Pharmaceuticals, Inc. crossed above their 200 day moving average of $6.49, changing hands as high as $6.65 per share.

Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today

Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today

Ariad Pharmaceuticals (ARIA) rose Tuesday as Roche's $8.3 billion acquisition of InterMune (ITMN) has led the biotech sector higher.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Why Ariad Pharmaceuticals (ARIA) Stock Is Down Today

Why Ariad Pharmaceuticals (ARIA) Stock Is Down Today

Ariad Pharmaceuticals (ARIA) shares are down after the company reported second quarter earnings and revenue that failed to meet analysts expectations.

ARIAD Reports Second Quarter 2014 Financial Results And Development Progress

ARIAD Reports Second Quarter 2014 Financial Results And Development Progress

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig ® (ponatinib).

ARIAD Announces Commercial Agreement For Iclusig (Ponatinib) In Israel

ARIAD Announces Commercial Agreement For Iclusig (Ponatinib) In Israel

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights...

3 Biotech Stocks Under $10 in Breakout Territory

3 Biotech Stocks Under $10 in Breakout Territory

These under-$10 biotech stocks are within range of triggering breakout trades.

Storm The Castle: ARIAD Pharmaceuticals (ARIA)

Storm The Castle: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today

ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

3 Huge Stocks to Trade (or Not)

3 Huge Stocks to Trade (or Not)

Here's how to trade some of the most active stocks on the market today.

'Fast Money' Recap: Facebook and Analysts' Expectations

'Fast Money' Recap: Facebook and Analysts' Expectations

The trading panel discussed why they like Facebook's earnings and why they'd avoid Cheesecake Factory.

ARIAD Pharmaceuticals Enters Oversold Territory (ARIA)

ARIAD Pharmaceuticals Enters Oversold Territory (ARIA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market

Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market

Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.

ARIAD To Webcast Conference Call On Second Quarter 2014 Financial Results

ARIAD To Webcast Conference Call On Second Quarter 2014 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens.

Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation

Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation

Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.

ARIAD Announces Continuation Of Iclusig Review Under The Article 20 Procedure In Europe

ARIAD Announces Continuation Of Iclusig Review Under The Article 20 Procedure In Europe

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has provided the Company with a request for limited...

Short Interest In ARIAD Pharmaceuticals Expands By 16%

Short Interest In ARIAD Pharmaceuticals Expands By 16%

The most recent short interest data has been released by the NASDAQ for the 06/30/2014 settlement date, which shows a 6,622,315 share increase in total short interest for ARIAD Pharmaceuticals, Inc. , to 48,055,172, an increase of 15.98% since 06/13/2014.

ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today

ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout

By Alex Gavrish, Etalon Investment Research; author of "Wall Street Back To Basics" The main beneficiary of a recent acquisition of Idenix Pharmaceuticals Inc (NASDAQ:IDIX) by Merck & Co., I...

Piet A.M Vervaet, M.D., Vice President, Drug Safety And Pharmacovigilance, ARIAD Pharmaceuticals, Inc. (Photo: Business Wire)

Piet A.M Vervaet, M.D., Vice President, Drug Safety And Pharmacovigilance, ARIAD Pharmaceuticals, Inc. (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the recent appointments of three executives with extensive pharmaceutical industry experience in the areas of global quality, medical affairs, and drug ...

Will This Price Target Decrease Hurt Ariad Pharmaceuticals (ARIA) Stock Today?

Will This Price Target Decrease Hurt Ariad Pharmaceuticals (ARIA) Stock Today?

UBS decreased its price target on Ariad Pharmaceuticals (ARIA) to $7 and set a "neutral" rating. The firm noted limited near-term drivers of upside risk.

ARIAD Announces Pricing Of $200 Million Offering Of 3.625% Convertible Senior Notes Due 2019

ARIAD Announces Pricing Of $200 Million Offering Of 3.625% Convertible Senior Notes Due 2019

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of $200 million aggregate principal amount of its 3.

Why Ariad Pharmaceuticals (ARIA) Stock Is Down in After-Hours Trading Today

Why Ariad Pharmaceuticals (ARIA) Stock Is Down in After-Hours Trading Today

Ariad Pharmaceuticals (ARIA) fell in after-hours trading Wednesday after the oncology company announced a proposed $175 million aggregate principal amount of convertible senior notes due 2019 in a private placement.

ARIAD Announces Proposed $175 Million Offering Of Convertible Senior Notes Due 2019

ARIAD Announces Proposed $175 Million Offering Of Convertible Senior Notes Due 2019

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the “Notes”)...